Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.79 |
| ▸ | MAPK14 | Q16539 | 20/20 | 0.79 |
| ▸ | TNNI3K | Q59H18 | 20/20 | 0.79 |
| ▸ | BRAF | P15056 | 18/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3186026 | 0.89 | KDR (0.79) | KDRMAPK14TNNI3KBRAF | |
| SCHEMBL3184177 | 0.89 | KDR (0.79) | KDRMAPK14TNNI3KBRAF | |
| SCHEMBL3180722 | 0.88 | KDR (1.00) | KDRMAPK14TNNI3KBRAF | |
| SCHEMBL9932848 | 0.86 | KDR (0.77) | KDRMAPK14TNNI3KBRAF | |
| SCHEMBL3171768 | 0.86 | KDR (1.00) | KDRMAPK14TNNI3KBRAF | |
| SCHEMBL9933046 | 0.86 | KDR (0.80) | KDRMAPK14TNNI3KBRAF | |
| SCHEMBL2762594 | 0.85 | KDR (0.76) | KDRMAPK14TNNI3KBRAF | |
| SCHEMBL3183280 | 0.85 | KDR (1.00) | KDRMAPK14TNNI3KBRAF | |
| SCHEMBL9931989 | 0.85 | KDR (0.77) | KDRMAPK14TNNI3KBRAF | |
| SCHEMBL1888544 | 0.85 | KDR (0.71) | KDRMAPK14TNNI3KBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652022-B2 | N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; | NOVARTIS AG (CH) | 2010-01-26 | — | — | US | claimed |
| EP-1511730-B8 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2009-04-08 | — | — | EP | claimed |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | FLOERSHEIMER ANDREAS | 2006-06-15 | — | — | US | claimed |
| EP-1511730-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-09 | — | — | EP | claimed |
| WO-2003099771-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | claimed |
| US-20130338168-A1 | Combinations of JAK Inhibitors | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| US-20100280003-A1 | COMBINATIONS OF JAK INHIBITORS | COOKE NIGEL GRAHAM | 2010-11-04 | — | — | US | disclosed |
| US-7652022-B2 | N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; | NOVARTIS AG (CH) | 2010-01-26 | — | — | US | disclosed |
| US-7652022-B2 | N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; | NOVARTIS AG (CH) | 2010-01-26 | — | — | US | disclosed |
| US-20090156602-A1 | Organic Compounds | COOKE NIGEL GRAHAM | 2009-06-18 | — | — | US | disclosed |
| EP-1511730-B8 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | BOLD GUIDO | 2008-12-18 | — | — | US | disclosed |
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | BOLD GUIDO | 2008-12-18 | — | — | US | disclosed |
| EP-1511730-B1 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2008-12-10 | — | — | EP | disclosed |
| US-20080207591-A1 | Organic Compounds | MANLEY PAUL W | 2008-08-28 | — | — | US | disclosed |
| EP-1689376-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | FLOERSHEIMER ANDREAS | 2006-06-15 | — | — | US | disclosed |
| WO-2005051366-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| EP-1511730-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003099771-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280003-A1 | COMBINATIONS OF JAK INHIBITORS | JAK2, JAK3, JAK1 | KDR 123/4885MAPK14 310/4885TNNI3K 357/4885 |
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | RET, PRKDC, PRKACA | KDR 1309/4885MAPK14 343/4885TNNI3K 314/4885 |
| US-20130338168-A1 | Combinations of JAK Inhibitors | JAK2, JAK3, JAK1 | KDR 123/4885MAPK14 310/4885TNNI3K 357/4885 |
| US-20080207591-A1 | Organic Compounds | FLT4, FLT1, FLT3 | KDR 7/4885MAPK14 2685/4885TNNI3K 1082/4885 |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | UCK2, PRKDC, PRKACA | KDR 3898/4885MAPK14 444/4885TNNI3K 340/4885 |
| US-20090156602-A1 | Organic Compounds | BTK, JAK2, JAK3 | KDR 74/4885MAPK14 497/4885TNNI3K 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.